According to Viridian Therapeutics's latest financial reports the company has a price-to-book ratio of 2.11.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 2.59 | -12.93% |
2022-12-31 | 2.98 | 18.11% |
2021-12-31 | 2.52 | 334.54% |
2020-12-31 | 0.5798 | -45.4% |
2019-12-31 | 1.06 | -41.65% |
2018-12-31 | 1.82 | -69.88% |
2017-12-31 | 6.04 | -153.02% |
2016-12-31 | -11.4 | -1591.27% |
2015-12-31 | 0.7642 | -52.35% |
2014-12-31 | 1.60 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | 2.71 | 28.47% | ๐บ๐ธ USA |